GREENWICH LIFESCIENCES, INC.: 10-K filed 2024-04-15
What GREENWICH LIFESCIENCES, INC. reported in its annual report filed 2024-04-15 (fiscal FY 2023): 21 published measures, 40 facts as tagged in accession 0001493152-24-014625.
This filing
- Form
- 10-K (annual report)
- Filed
- 2024-04-15
- Fiscal period
- fiscal FY 2023
- Accession
- 0001493152-24-014625 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All GREENWICH LIFESCIENCES, INC. filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-12-31 | 6,994,815 | USD | |
| At 2022-12-31 | 13,477,029 | USD |
Total liabilities
Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-12-31 | 294,406 | USD | |
| At 2022-12-31 | 262,905 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-12-31 | 6,700,409 | USD | |
| At 2022-12-31 | 13,214,124 | USD | |
| At 2021-12-31 | 26,831,712 | USD |
Cash and cash equivalents
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-12-31 | 6,989,424 | USD | |
| At 2022-12-31 | 13,468,026 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-01-01 to 2023-12-31 | -8,891,803 | USD | 365 |
| 2022-01-01 to 2022-12-31 | -7,825,237 | USD | 365 |
Operating cash flow
Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-01-01 to 2023-12-31 | -6,478,602 | USD | 365 |
| 2022-01-01 to 2022-12-31 | -6,200,027 | USD | 365 |
Financing cash flow
Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-01-01 to 2022-12-31 | -7,536,216 | USD | 365 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-12-31 | -50,364,569 | USD | |
| At 2022-12-31 | -41,472,766 | USD |
Diluted weighted-average shares
Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-01-01 to 2023-12-31 | 12,848,165 | shares | 365 |
| 2022-01-01 to 2022-12-31 | 12,913,848 | shares | 365 |
Basic earnings per share
Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-01-01 to 2023-12-31 | -0.69 | USD/shares | 365 |
| 2022-01-01 to 2022-12-31 | -0.61 | USD/shares | 365 |
Diluted earnings per share
Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-01-01 to 2023-12-31 | -0.69 | USD/shares | 365 |
| 2022-01-01 to 2022-12-31 | -0.61 | USD/shares | 365 |
Share-based compensation expense
Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-01-01 to 2023-12-31 | 2,378,088 | USD | 365 |
| 2022-01-01 to 2022-12-31 | 1,743,865 | USD | 365 |
Operating income or loss
Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-01-01 to 2023-12-31 | -9,327,866 | USD | 365 |
| 2022-01-01 to 2022-12-31 | -8,040,254 | USD | 365 |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-12-31 | 294,406 | USD | |
| At 2022-12-31 | 262,905 | USD |
Net finite-lived intangible assets
Finite-lived intangible assets after amortization. This excludes goodwill and should not be combined with indefinite-lived intangible assets without checking scope.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-12-31 | 5,391 | USD | |
| At 2022-12-31 | 9,003 | USD |
Common-stock repurchase payments
Cash paid to reacquire common stock during the period. This is not an authorization limit or a direct measure of the net change in share count.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-01-01 to 2022-12-31 | 7,536,216 | USD | 365 |
Operating expenses
Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-01-01 to 2023-12-31 | 9,327,866 | USD | 365 |
| 2022-01-01 to 2022-12-31 | 8,040,254 | USD | 365 |
Research and development expense
Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-01-01 to 2023-12-31 | 7,698,622 | USD | 365 |
| 2022-01-01 to 2022-12-31 | 6,475,668 | USD | 365 |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-12-31 | 12,848,165 | shares | |
| At 2022-12-31 | 12,848,165 | shares |
General and administrative expense
General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-01-01 to 2023-12-31 | 1,629,244 | USD | 365 |
| 2022-01-01 to 2022-12-31 | 1,564,586 | USD | 365 |
Change in accounts payable
The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-01-01 to 2023-12-31 | 35,472 | USD | 365 |
Inspect the source
- Entity
- GREENWICH LIFESCIENCES, INC. / CIK 0001799788
- Captured
- 2026-09-21T17:27:54.821Z
- SEC response SHA-256
a617dbe92932ff09e9921f2bebe266085b6d33d46c3d873a6ff42dd23172a3bb
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001799788.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))